Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2015 | Pages:
225 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Summary Global Markets Direct's, 'Spinal cord Injury - Pipeline Review, H2 2015', provides an overview of the Spinal cord Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Spinal cord Injury The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Spinal cord Injury and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Spinal cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Spinal cord Injury pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Spinal cord Injury Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Spinal cord Injury pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Spinal Cord Injury Overview 9 Therapeutics Development 10 Pipeline Products for Spinal Cord Injury - Overview 10 Pipeline Products for Spinal Cord Injury - Comparative Analysis 11 Spinal Cord Injury - Therapeutics under Development by Companies 12 Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 16 Spinal Cord Injury - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 Spinal Cord Injury - Products under Development by Companies 19 Spinal Cord Injury - Products under Investigation by Universities/Institutes 23 Spinal Cord Injury - Companies Involved in Therapeutics Development 25 Acorda Therapeutics, Inc. 25 Asubio Pharma Co., Ltd. 26 Athersys, Inc. 27 Axerion Therapeutics, Inc. 28 BioArctic Neuroscience AB 29 Cortex Pharmaceuticals, Inc. 30 Faron Pharmaceuticals Oy 31 FirstString Research, Inc. 32 Genervon Biopharmaceuticals, LLC 33 Grupo Ferrer Internacional, S.A. 34 Hemostemix Ltd 35 Histocell S.L. 36 K-Stemcell Co., Ltd. 37 Kadimastem Ltd. 38 Kringle Pharma, Inc. 39 Lipopharma Therapeutics SL 40 Lpath, Inc. 41 MandalMed, Inc. 42 Mapreg S.A.S. 43 Mitsubishi Tanabe Pharma Corporation 44 Neuralstem, Inc. 45 Neuronax SAS 46 Omeros Corporation 47 PharmatrophiX, Inc. 48 Pharmicell Co., Ltd. 49 Q Therapeutics, Inc. 50 Quark Pharmaceuticals, Inc. 51 Remedy Pharmaceuticals, Inc. 52 RhinoCyte, Inc. 53 SanBio, Inc. 54 Sirnaomics, Inc. 55 StemCells, Inc. 56 Stemedica Cell Technologies, Inc. 57 TissueGene, Inc. 58 Vertex Pharmaceuticals Incorporated 59 Vicore Pharma AB 60 Spinal Cord Injury - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 68 Assessment by Molecule Type 70 Drug Profiles 72 (buspirone + levodopa + carbidopa) - Drug Profile 72 ACTX-08 - Drug Profile 73 Antibody to Inhibit RGM for Spinal Cord Injury - Drug Profile 74 AP-325 - Drug Profile 75 AST-OPC-1 - Drug Profile 76 Astrostem - Drug Profile 78 AX-007 - Drug Profile 79 BA-277 - Drug Profile 80 BA-434 - Drug Profile 81 C-21 - Drug Profile 82 Cell Therapy for Spinal Cord Injury - Drug Profile 84 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 85 Cerecellgram-Spine - Drug Profile 87 CHEC-7 - Drug Profile 88 CHEC-9 - Drug Profile 89 chondroitinase ABC nanosphere - Drug Profile 91 cimaglermin alfa - Drug Profile 92 CLR-01 - Drug Profile 94 CM-101 - Drug Profile 95 CX-1739 - Drug Profile 96 CX-717 - Drug Profile 98 Drug for Spinal Cord Injury - Drug Profile 100 Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 101 FIB-117 - Drug Profile 102 glyburide - Drug Profile 103 GM-603 - Drug Profile 105 HBN-1 - Drug Profile 106 HC-016 - Drug Profile 107 HuCNS-SC - Drug Profile 108 ICCN-100 - Drug Profile 110 IMS-001 - Drug Profile 111 IMS-002 - Drug Profile 112 interferon beta-1a - Drug Profile 113 KP-100IT - Drug Profile 115 LM11A-31 - Drug Profile 117 LPA-181 - Drug Profile 118 Lpathomab - Drug Profile 119 MAP-4343 - Drug Profile 120 MultiStem - Drug Profile 121 NCP-01 - Drug Profile 125 Neural Stem Cells - Drug Profile 126 neurovitas - Drug Profile 128 NgR(310)ecto-Fc - Drug Profile 129 NSI-566 - Drug Profile 131 NX-210 - Drug Profile 133 Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 134 Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile 135 Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 136 PT-00114 - Drug Profile 137 Q-Cells - Drug Profile 138 Recombinant Protein for Spinal Cord Injury - Drug Profile 140 SB-618 - Drug Profile 141 SB-623 - Drug Profile 142 SC-0806 - Drug Profile 144 siRNA for CNS Disorders - Drug Profile 146 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 147 Small Molecules for Spinal Cord Injury - Drug Profile 148 Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile 149 Stem Cell Therapy for CNS Disorders - Drug Profile 150 Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 151 Stem Cell Therapy for Spinal Cord Injury - Drug Profile 153 Stem Cell Therapy for Spinal Cord Injury - Drug Profile 154 Stem Cell Therapy Program for Neurodegenerative Diseases - Drug Profile 155 STP-805 - Drug Profile 156 SUN-13837 - Drug Profile 157 Synthetic Peptide for Spinal Cord Injuries - Drug Profile 158 Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile 159 Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 160 Tenascin-C Fragments for Spinal Cord Injury - Drug Profile 161 TG-N - Drug Profile 163 UH-0113 - Drug Profile 164 UH-0213 - Drug Profile 165 VX-210 - Drug Profile 166 Spinal Cord Injury - Recent Pipeline Updates 169 Spinal Cord Injury - Dormant Projects 206 Spinal Cord Injury - Discontinued Products 208 Spinal Cord Injury - Product Development Milestones 209 Featured News & Press Releases 209 Appendix 219 Methodology 219 Coverage 219 Secondary Research 219 Primary Research 219 Expert Panel Validation 219 Contact Us 219 Disclaimer 220
List of Tables Number of Products under Development for Spinal Cord Injury, H2 2015 15 Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2015 16 Number of Products under Development by Companies, H2 2015 18 Number of Products under Development by Companies, H2 2015 (Contd..1) 19 Number of Products under Development by Companies, H2 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2015 21 Comparative Analysis by Clinical Stage Development, H2 2015 22 Comparative Analysis by Early Stage Development, H2 2015 23 Products under Development by Companies, H2 2015 24 Products under Development by Companies, H2 2015 (Contd..1) 25 Products under Development by Companies, H2 2015 (Contd..2) 26 Products under Development by Companies, H2 2015 (Contd..3) 27 Products under Investigation by Universities/Institutes, H2 2015 28 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 29 Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H2 2015 30 Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H2 2015 31 Spinal Cord Injury - Pipeline by Athersys, Inc., H2 2015 32 Spinal Cord Injury - Pipeline by Axerion Therapeutics, Inc., H2 2015 33 Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H2 2015 34 Spinal Cord Injury - Pipeline by Cortex Pharmaceuticals, Inc., H2 2015 35 Spinal Cord Injury - Pipeline by Faron Pharmaceuticals Oy, H2 2015 36 Spinal Cord Injury - Pipeline by FirstString Research, Inc., H2 2015 37 Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015 38 Spinal Cord Injury - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 39 Spinal Cord Injury - Pipeline by Hemostemix Ltd, H2 2015 40 Spinal Cord Injury - Pipeline by Histocell S.L., H2 2015 41 Spinal Cord Injury - Pipeline by K-Stemcell Co., Ltd., H2 2015 42 Spinal Cord Injury - Pipeline by Kadimastem Ltd., H2 2015 43 Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2015 44 Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H2 2015 45 Spinal Cord Injury - Pipeline by Lpath, Inc., H2 2015 46 Spinal Cord Injury - Pipeline by MandalMed, Inc., H2 2015 47 Spinal Cord Injury - Pipeline by Mapreg S.A.S., H2 2015 48 Spinal Cord Injury - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 49 Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2015 50 Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2015 51 Spinal Cord Injury - Pipeline by Omeros Corporation, H2 2015 52 Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H2 2015 53 Spinal Cord Injury - Pipeline by Pharmicell Co., Ltd., H2 2015 54 Spinal Cord Injury - Pipeline by Q Therapeutics, Inc., H2 2015 55 Spinal Cord Injury - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 56 Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015 57 Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H2 2015 58 Spinal Cord Injury - Pipeline by SanBio, Inc., H2 2015 59 Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H2 2015 60 Spinal Cord Injury - Pipeline by StemCells, Inc., H2 2015 61 Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2015 62 Spinal Cord Injury - Pipeline by TissueGene, Inc., H2 2015 63 Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 64 Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2015 65 Assessment by Monotherapy Products, H2 2015 66 Assessment by Combination Products, H2 2015 67 Number of Products by Stage and Target, H2 2015 69 Number of Products by Stage and Mechanism of Action, H2 2015 72 Number of Products by Stage and Route of Administration, H2 2015 74 Number of Products by Stage and Molecule Type, H2 2015 76 Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2015 174 Spinal Cord Injury - Dormant Projects, H2 2015 211 Spinal Cord Injury - Dormant Projects (Contd..2), H2 2015 212 Spinal Cord Injury - Discontinued Products, H2 2015 213
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
